Bibliometric analysis of randomized controlled trials of colorectal cancer over the last decade

Table 1 The top 10 research institutions by publication

Institution	Country	Number
Harvard University	United States	52
University of California	United States	51
University of Texas	United States	41
University of London	United Kingdom	40
University of Toronto	Canada	33
Boston Healthcare System	United States	30
NIH National Institute of Health	United States	29
University College London	United Kingdom	25
National Cancer Institute NCI	United States	24
Mayo Clinic	United States	24

Table 2 Top 20 journals by publication

Journal	Number	IF 2017	Country
Journal of Clinical Oncology	84	26.3	United States
Annals of Oncology	69	13.93	United Kingdom
BMC Cancer	55	3.29	United Kingdom
The Lancet Oncology	49	36.42	United States
Trials	42	2.07	United Kingdom
European Journal of Cancer	38	7.19	United Kingdom
British Journal of Surgery	36	5.43	United Kingdom
International Journal of Colorectal Disease	32	2.53	Germany
British Journal of Cancer	32	5.92	United Kingdom
Annals of Surgery	32	9.2	United States
Diseases of the Colon and Rectum	28	3.62	United States
Colorectal Disease	28	2.78	United Kingdom
Cancer	26	6.54	United States
Chinese Journal of Gastrointestinal Surgery	23		China
Surgical Endoscopy	23	3.12	United States
Clin Colorectal Cancer	21	3.86	United States
Lancet	17	53.25	United Kingdom
Cancer Epidemiology	17	2.89	United Kingdom
Gut	15	17.02	United Kingdom
BMJ Open	15	2.41	United Kingdom

IF: Impact factor.

Table 3 Top 10 cited colorectal cancer randomized controlled trial-related literature in the domestic and international publications in 2008-2018

Ref.	Title	Journal	Cited	Year
Nordlinger et al[3]	Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomized controlled trial	Lancet	1104	2008
Atkin et al[4]	Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: A multicentre randomised controlled trial	Lancet	961	2010
Grothey et al[5]	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial	Lancet	935	2013
Tol et al[6]	Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer	New England Journal of Medicine	904	2009
Baxter et al[7]	Association of colonoscopy and death from colorectal cancer	Annals of Internal Medicine	835	2009
Hecht et al[8]	A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer	Journal of Clinical Oncology	596	2009
Maughan et al[9]	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial	Lancet	574	2011
Peeters et al[10]	Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer	Journal of Clinical Oncology	549	2010
Folprecht et al[11]	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial	Lancet Oncology	523	2010
Verwaal et al[12]	8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer	Annals of Surgical Oncology	448	2008